Superficial Candidiasis: Cluster Analysis of Species Distribution and Their Antifungal Susceptibility In Vitro
Journal of Fungi · 25.04.2025 · 11 (5) · 338
DOI: 10.3390/jof11050338 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Fungi, online erschienen am 25.04.2025. Verfasst von Marina Ranđelović und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Medical Faculty, University of Niš, 18000 Niš, Serbia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation of the Republic of Serbia, Science Fund of the Republic of Serbia.
Abstract (Originalsprache)
Background
Superficial candidiasis (SC) is widespread in humans worldwide. This study aimed to evaluate species distribution patterns and antifungal susceptibility through cluster analysis.
Methods
A total of 180 Candida strains isolated from skin and nail samples of 1593 examined patients with suspected superficial fungal infection were identified by Matrix-assisted laser desorption in ionization-time of flight mass spectrometry (MALDI-TOF MS; Zybio EXS2600, China). Antifungal susceptibility was assessed using the commercial Integral System YEASTS Plus test (ISYPT; Liofilchem®, Italy). Agglomerative hierarchical cluster analysis was used to analyze species distribution and susceptibility.
Results
Candida parapsilosis (44.4%) and C. albicans (40%) were the most prevalent causative agents of SC. Cluster analysis established two defined clusters. Cluster 1 (121 isolates) showed a statistically significant difference compared to Cluster 2 (54 isolates) in species distribution (C. albicans was dominant in the first and C. parapsilosis in the second cluster) as well as in susceptibility to ECN (p ≤ 0.001), KCA (p = 0.030), CLO (p ≤ 0.001), MCZ (p ≤ 0.001), ITZ (p ≤ 0.001), and FLU (p ≤ 0.006).
Conclusion
The fact that one-third of isolates exhibited low sensitivity to antifungals highlights the need for a new approach in SC treatment, emphasizing the importance of mycological analyses, including in vitro testing of antifungal effectiveness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Medical Faculty, University of Niš, 18000 Niš, Serbia.
- Centre of Microbiology, Public Health Institute Niš, 18000 Niš, Serbia.
- Department of Medical Statistics and Informatics, Medical Faculty, University of Niš, 18000 Niš, Serbia.
- Department of Dermatology, Clinical Center, University of Niš, 18000 Niš, Serbia.
- Department of Physiology, Medical Faculty, University of Priština-Kosovska Mitrovica, 38000 Kosovska Mitrovica, Serbia.
- Doctoral Studies, Faculty of Medicine, University of Niš, 18000 Niš, Serbia.
ORCID-Profile: Marina Ranđelović, Aleksandra Ignjatović, Marko Stalević, Nataša Rančić, Suzana Otašević
Förderung
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia
- Science Fund of the Republic of Serbia
Zitieren
APA
Ranđelović, M., Ignjatović, A., Đorđević, M., Golubović, M., Stalević, M., Rančić, N., & Otašević, S. (2025). Superficial Candidiasis: Cluster Analysis of Species Distribution and Their Antifungal Susceptibility In Vitro. Journal of Fungi, 11(5), 338. https://doi.org/10.3390/jof11050338
Vancouver
Ranđelović M, Ignjatović A, Đorđević M, Golubović M, Stalević M, Rančić N, et al. Superficial Candidiasis: Cluster Analysis of Species Distribution and Their Antifungal Susceptibility In Vitro. Journal of Fungi. 2025;11(5):338. doi:10.3390/jof11050338
BibTeX
@article{Ranelovi2025,
author = {Ranđelović, Marina and Ignjatović, Aleksandra and Đorđević, Milica and Golubović, Maša and Stalević, Marko and Rančić, Nataša and Otašević, Suzana},
title = {Superficial Candidiasis: Cluster Analysis of Species Distribution and Their Antifungal Susceptibility In Vitro},
journal = {Journal of Fungi},
year = {2025},
volume = {11},
number = {5},
pages = {338},
doi = {10.3390/jof11050338}
}
EUVIMED